Claims
- 1. An antibiotic AM-2604-A substance having the following properties:
- (a) Molecular formula: C.sub.48 H.sub.71 NO.sub.14 ;
- (b) Optical rotation: [.alpha.].sub.D.sup.27.5 =+240.degree. (C=0.02, methanol);
- (c) Melting point: 204.degree. to 205.degree. C.;
- (d) Ultraviolet absorption spectrum: as shown in FIG. 1;
- (e) Infrared absorption spectrum as shown in FIG. 2;
- (f) Proton nuclear magnetic resonance spectrum as shown in FIG. 3;
- (g) .sup.13 C Nuclear magnetic resonance spectrum as shown in FIG. 4; and
- (h) Soluble in chloroform, acetone, and ethyl acetate, sparingly soluble in lower alcohols, and insoluble in n-hexane and water ##STR2##
- 2. An antibiotic AM-2604-A substance as in claim 1 having the additional properties:
- (i) a positive color reaction to: a ferric chloride reaction, a permanganic acid reaction, an anisaldehyde sulfuric acid reaction, and a p-anisidine hydrochloric salt reaction; a negative color reaction to a Dragendorff reaction and a ninhydrin reaction;
- (j) a pale yellow color;
- (k) the following Rf values measured on silica gel thin layer chromatography, with the corresponding solvent:
- (i) chloroform/methanol (9:1): -Rf: 0.54
- (ii) chloroform/methanol (4:1): -Rf: 0.73
- (iii) benzene/acetone (1:1): -Rf: 0.58
- (iv) benzene/methanol (2:1): -Rf: 0.70
- (v) ethyl acetate: -Rf: 0.36
- (vi) ethanol/water (4:1): -Rf: 0.81.
- 3. An anti-trichomonas composition comprising a pharmaceutical effective amount of the antibiotic as defined in claim 1 as an active component and a pharmaceutically acceptable diluent or carrier.
- 4. An anti-coccidium composition comprising a pharmaceutical effective amount of the antibiotic as defined in claim 1 as an active component and a pharmaceutically acceptable diluent or carrier.
- 5. An anti-viral composition comprising a pharmaceutical effective amount of the antibiotic as defined in claim 1 as an active component and a pharmaceutically acceptable diluent or carrier.
- 6. An anti-fungal composition comprising a pharmaceutical effective amount of the antibiotic as defined in claim 1 as an active component and a pharmaceutically acceptable diluent or carrier.
- 7. An anti-viral composition as in claim 5, wherein said agent is an anti-DNA virus agent.
- 8. An anti-viral composition as in claim 5, wherein said agent is an anti-RNA virus agent.
- 9. The anti-trichomonas composition as in claim 3, wherein acceptable diluents or carriers are selected from the group consisting of CaCO.sub.3, lactose, sucrose, gelatin, polyvinyl pyrrolidone and cyclodextorin.
- 10. A method for treating human, animal and plant diseases due to fungi comprising administering a pharmaceutically effective amount of the antibiotic as defined in claim 1.
- 11. A method for treating human, animal and plant diseases due to virus comprising administering a pharmaceutically effective amount of the antibiotic as defined in claim 1.
- 12. A method for treating human and animal diseases due to coccidium comprising administering a pharmaceutically effective amount of the antibiotic as defined in claim 1.
- 13. A method for treating human and animal diseases due to trichomonas comprising administering a pharmaceutically effective amount of the antibiotic as defined in claim 1.
- 14. The method as in claim 11, wherein said agent is administered orally, intravenously, subcutaneously, intraperitoneally or rectally in the form of a suppository.
- 15. The method as in claim 12, wherein said agent is administered orally, intravenously, subcutaneously, intraperitoneally or rectally in the form of a suppository.
- 16. The method as in claim 13, wherein said agent is administered orally, intravenously, subcutaneously, intraperitoneally or rectally in the form of a suppository.
- 17. A method as in claim 13, wherein when said antibiotic is used in the treatment of humans and animal diseases due to trichomonas, the administered dose is from 0.20-10 mg/kg of the subject and the number of administrations is from 1-6 per day.
- 18. The method as in claim 10, wherein said agent is administered orally, intravenously, subcutaneously, intraperitoneally or rectally in the form of a suppository.
Priority Claims (1)
Number |
Date |
Country |
Kind |
57-6756 |
Jan 1982 |
JPX |
|
Parent Case Info
This is a division of application Ser. No. 459,912 filed Jan. 21, 1983, now U.S. Pat. No. 4,503,152, now issued Mar. 5, 1985.
Foreign Referenced Citations (1)
Number |
Date |
Country |
0042697 |
Mar 1982 |
JPX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
459912 |
Jan 1983 |
|